Latest Regulatory Milestones News

Wia Gold is making steady progress on its Kokoseb Gold Project in Namibia, reporting strong high-grade drilling results that bolster underground mining prospects alongside ongoing feasibility studies and strategic leadership appointments.

Leeuwin Metals has secured Mining Lease M77/1300 over the Evanston deposit, marking a crucial step toward development at its Marda Gold Project. All current Mineral Resources at Marda now reside on granted leases, underpinning future production plans amid ongoing exploration.

Atomo Diagnostics has responded to ASX queries confirming it first held market-sensitive information after Lumos Diagnostics’ FDA CLIA waiver approval for FebriDx. The company defended its trading halt and capital raise timing, asserting full compliance with ASX Listing Rules.

Macarthur Minerals (ASX:MIO) has clarified the timing of its cleansing notice relative to a key Programme of Work approval, affirming compliance with ASX continuous disclosure rules and explaining the rationale behind delayed disclosure.

Predictive Discovery and Robex Resources have completed all merger steps except the final administrative confirmation from Quebec, bringing the combined West African gold producer closer to operational integration.

Neurizon Therapeutics has secured an additional A$2.7 million through a placement addressing the shortfall from its entitlement offer, lifting total proceeds to approximately A$8.5 million. This fresh capital strengthens the biotech’s balance sheet and provides financial flexibility as it advances its lead ALS drug NUZ-001 through pivotal clinical stages.

BlinkLab has secured A$17.5 million through an oversubscribed placement to fuel regulatory trials and commercial launch of its AI-driven autism and ADHD diagnostic tools.

Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.

Riversgold Limited has reported standout assay results from 31 drill holes at its Northern Zone Gold Project, including a spectacular 71 g/t gold intercept. The campaign expands the shallow gold mineralisation footprint, supporting imminent mining lease conversion and a funding agreement with MEGA Resources.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

Vysarn Limited's joint venture with Kariyarra Aboriginal Corporation has been shortlisted by Water Corporation to submit a formal proposal for supplying bulk water to Port Hedland, progressing key regulatory approvals for the Kariyarra Water Scheme.

Telix Pharmaceuticals has initiated a US$550 million convertible bonds offering to refinance existing 2029 bonds and support general corporate purposes, securing low-cost, non-dilutive financing with a conversion premium above current share price.